Recent evidence demonstrates that “trans” IL-6 signaling, involving extracellular binding of IL-6 and its soluble receptor is more important for the osteoclastogenic response to IL-6 in rheumatoid arthritis, estrogen deficiency, and colitis [1]. Here, IL6 is linked to colitis.